Yoichi Naito

4.9k citations

150 papers · 2.7k indexed · 2 hit papers · h-index 27

Impact in

Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
Gastroenterology top 2%
- Gastrointestinal Tumor Research and Treatment

Papers in

Oncology 98
- HER2/EGFR in Cancer Research 34
- Cancer Treatment and Pharmacology 29
Gastroenterology 19
- Gastrointestinal Tumor Research and Treatment 19

Co-authors: Toshihiko Doi Nobuaki Matsubara Toshirou Nishida Kohei Shitara Yutaka Nishiwaki Hirofumi Mukai Tetsuya Urasaki Kaoru Kubota
Journals: Journal of Clinical Oncology (24 papers)Annals of Oncology (21 papers)Cancer Science (10 papers)International Journal of Clinical Oncology (7 papers)Investigational New Drugs (6 papers)
Partner nations: Japan United States United Kingdom

In The Last Decade

Yoichi Naito

141 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study 2024 · 43 citations

Peers

Countries citing papers authored by Yoichi Naito

Since Specialization

Citations

This map shows the geographic impact of Yoichi Naito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoichi Naito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoichi Naito more than expected).

Fields of papers citing papers by Yoichi Naito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoichi Naito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoichi Naito. The network helps show where Yoichi Naito may publish in the future.

Co-authors

The 25 scholars most cited alongside Yoichi Naito, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yoichi Naito Line = papers co-authored together Yoichi Naito links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer Clinical Cancer Research ·Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton, Yoichi Naito, Antonio Giordano, Igor Bondarenko, Toshinari Yamashita, Li Zhou, Allison Moreau, Heather Neumann, Jessica Tougias, Feng Liu, Jennifer Park, Maria Delioukina, Komal Jhaveri	2025	5
2	Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025 The Journal of Dermatology ·Yasuhiro Fujisawa, Yasuo Yoshioka, Koji Yoshino, Taku Fujimura, Yoichi Naito, Mamiko Masuzawa, Kohei Oashi, Eiji Nakano, Hiroshi Kato, Yusuke Muto, Hiroshi Koga, Tomomitsu Miyagaki, Hiroshi Uchi, Yasuhiro Nakamura, Kenji Asagoe	2025	1
3	Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors International Journal of Clinical Oncology ·Yoichi Naito, Seigo Nakamura, Nobuko Kawaguchi‐Sakita, Takanori Ishida, T. Nakayama, Yutaka Yamamoto, Norikazu Masuda, Koji Matsumoto, Takahiro Kogawa, Kazuki Sudo, Akihiko Shimomura, Catherine Lai, Danjie Zhang, Yuki Iwahori, Dianna Gary, Danh Huynh, Hiroji Iwata	2024	4
4	Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance Gynecologic Oncology Reports ·Takehiro Nakao, Kenichi Harano, Masashi Wakabayashi, Yoichi Naito, Hiroshi Tanabe, Toru Mukohara	2024	0
5	PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study Cancer Medicine ·Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu	2024	9
6	654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study Annals of Oncology ·Bob T. Li, Funda Meric‐Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian C. Anderson, Giuseppe Curigliano, Maria J. de Miguel, Mamta Kalra, D-Y. Oh, J.O. Park, Sophie Postel‐Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Aaron Smith, K. K. Machado, C. Saura Manich	2023	19
7	1917MO CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor Annals of Oncology ·Yoichi Naito, Yoshito Komatsu, Yukinori Kurokawa, Hidekazu Hirano, Toshirou Nishida, Toshihiko Doi	2023	1
8	The impact of the COVID‐19 pandemic on perioperative chemotherapy for breast cancer Cancer Medicine ·Kaede Baba, Megumi Kawamoto, Kanako Mamishin, Mao Uematsu, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Hiromichi Nakajima, Chikako Funasaka, Takehiro Nakao, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara	2023	3
9	A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Clinical Cancer Research ·Suzanne George, Michael C. Heinrich, Neeta Somaiah, Peter Oppelt, Robert McLeod, Satoshi Nishioka, Madan G. Kundu, Xiaozhong Qian, Prasanna Kumar, Abderrahmane Laadem, Yvonne Lau, Brittany P. Tran, Maura Fallon, Ololade Dosunmu, Julia Shi, Yoichi Naito	2023	9
10	Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients. PubMed ·Yuko Abe, Naruto Taira, Kosuke Kashiwabara, Junji Tsurutani, Masahiro Kitada, Masato Takahashi, Hiroaki Kato, Yuichiro Kikawa, Eiko Sakata, Yoichi Naito, Yoshie Hasegawa, Tsuyoshi Saito, Tsutomu Iwasa, Tsutomu Takashima, Tomohiko Aihara, Hirofumi Mukai, Fumikata Hara, Tadahiko Shien, Hiroyoshi Doihara, Shinichi Toyooka	2022	1
11	Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer The Breast ·Hiromichi Nakajima, Kenichi Harano, Tokiko Nakai, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Shuichi Mitsunaga, Genichiro Ishii, Toru Mukohara	2022	11
12	Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors Cancer Science ·Toshihiko Doi, Kohei Shitara, Takashi Kojima, Yasutoshi Kuboki, Nobuaki Matsubara, Hideaki Bando, Kiyotaka Yoh, Yoichi Naito, Hiroshi Hirai, Yukinori Kurokawa, Terufumi Kato, Chigusa Morizane	2022	23
13	Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study Cancer Medicine ·Toshihiko Doi, Noboru Yamamoto, Yoichi Naito, Yasutoshi Kuboki, Takafumi Koyama, Yongzhe Piao, Naoto Tsujimoto, Hiroya Asou, Kōichi Inoue, Shunsuke Kondo	2021	7
14	Gastric mesenchymal tumor with smooth muscle differentiation and echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase (EML4‐ALK) fusion Pathology International ·Eigo Akimoto, Masanori Tokunaga, Reo Sato, Akihiko Yoshida, Yoichi Naito, Riu Yamashita, Takahiro Kinoshita, Takeshi Kuwata	2021	2
15	TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704) Clinical Cancer Research ·Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Kenichi Harano, Yoichi Naito, Mitsuko Suzuki, Miki Fukutani, Tsukiko Higuchi, Takashi Ikeno, Masashi Wakabayashi, Akihiro Sato, Shohei Koyama, Hiroyoshi Nishikawa, Kohei Shitara	2021	41
16	The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis The Breast ·Chikako Funasaka, Yoichi Naito, Shota Kusuhara, Takehiro Nakao, Yoko Fukasawa, Kanako Mamishin, Ayumi Komuro, Mashiro Okunaka, Chihiro Kondoh, Kenichi Harano, Takahiro Kogawa, Nobuaki Matsubara, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara	2021	6
17	Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study Investigational New Drugs ·Yoichi Naito, Yasutoshi Kuboki, Masafumi Ikeda, Kenichi Harano, Nobuaki Matsubara, Shigeyuki Toyoizumi, Yuko Mori, Natsuki Hori, Takashi Nagasawa, Takahiro Kogawa	2021	9
18	Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study Investigational New Drugs ·Akira Kawai, Norifumi Naka, Akihiko Shimomura, Shunji Takahashi, Shigehisa Kitano, Yoshinori Imura, Kan Yonemori, Fumihiko Nakatani, Shintaro Iwata, Eisuke Kobayashi, Hidetatsu Outani, Hironari Tamiya, Yoichi Naito, Noboru Yamamoto, Toshihiko Doi	2021	7
19	Phase I expansion cohort of TAS-115, a novel oral MET/VEGFR/FMS inhibitor, for castration-resistant prostate cancer patients (CRPC pts) with bone metastases Annals of Oncology ·Nobuaki Matsubara, Yoichi Naito, M. Sasaki, Norio Yamamoto, Shunji Takahashi, Hiroji Uemura, Toshihiko Doi	2017	1
20	Impact of Preexisting Pulmonary Fibrosis Detected on Chest Radiograph and CT on the Development of Gefitinib-Related Interstitial Lung Disease American Journal of Clinical Oncology ·Yoichi Naito, Satoshi Tsuchiya, Shinichi Ishihara, Koichi Minato, Yoshinori Shitara, Atsushi Takise, Tatsuo Suga, Akira Mogi, Katsumi Yamabe, Ryusei Saito	2008	21

About Yoichi Naito

Yoichi Naito is a scholar working on Oncology, Gastroenterology, Cancer Research, Pulmonary and Respiratory Medicine and Genetics, having authored 150 papers that have together received 2.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (34 papers), Cancer Treatment and Pharmacology (29 papers), Advanced Breast Cancer Therapies (20 papers), Gastrointestinal Tumor Research and Treatment (19 papers), Breast Cancer Treatment Studies (17 papers), Lung Cancer Treatments and Mutations (17 papers), Gastric Cancer Management and Outcomes (16 papers) and Cancer Genomics and Diagnostics (16 papers). The work is most often cited by research in Oncology (1.7k citations), Gastroenterology (199 citations), Pulmonary and Respiratory Medicine (1.1k citations), Cancer Research (428 citations) and Immunology (355 citations). Yoichi Naito has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Toshihiko Doi, Nobuaki Matsubara, Toshirou Nishida, Kohei Shitara, Yutaka Nishiwaki, Hirofumi Mukai, Tetsuya Urasaki, Kaoru Kubota, Yasutoshi Kuboki and Nagahiro Saijo. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Science, International Journal of Clinical Oncology and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact